Zhiwei Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhiwei Xiao has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Xuewu Huang
The First Clinical Medical College, Guangzhou University of Chinese Medicine, China
3 shared publications Chongkai Fang
2 shared publications- Jietao Lin
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
2 shared publications - Ahmed Haider
Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
1 shared publication - Arthur Christopoulos
Monash University
1 shared publication Ben'Ai Cheng
School of Environment and Chemical Engineering Tianjin Polytechnic University
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (3) , 243
Yifei Sanjie Formula in improving the response to PD-1 blockade by lung cancer through the attenuation of the USP7-NR1H4-bile acid metabolism axis
Original Article Yifei Sanjie Formula in improving the response to PD-1 blockade by lung cancer through the attenuation of the USP7-NR1H4-bile acid metabolism axis Yangzi Ren, Yuanliang Li, Chongkai Fang, Zhiqiang Chen, Zhiwei Xiao
- 1 March 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (3) , 243
Open AccessYifei Sanjie Formula in improving the response to PD-1 blockade by lung cancer through the attenuation of the USP7-NR1H4-bile acid metabolism axis
Original Article Yifei Sanjie Formula in improving the response to PD-1 blockade by lung cancer through the attenuation of the USP7-NR1H4-bile acid metabolism axis Yangzi Ren, Yuanliang Li, Chongkai Fang, Zhiqiang Chen, Zhiwei Xiao
- Open Access
- 27 September 2022
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2022, 1-13
The Prognostic Value of Serum Apolipoprotein A-I Level and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Liver Metastasis
Background. Colorectal cancer liver metastasis (CRLM) is a high degree of malignancy with rapid disease progression and has a poor prognosis. Both serum apolipoprotein A-I (ApoA-I) and neutrophil-to-lymphocyte ratio (NLR) play key roles in anti-inflammation and antitumor. This study is aimed at evaluating the implication of serum ApoA-I level in combination with NLR in the prognosis of CRLM. Methods. We retrospectively analyzed the serum ApoA-I level and NLR in 237 patients with CRLM. Cox regression analyses were used to identify the independent prognostic significance of these indicators. Kaplan-Meier method and Log-rank test were applied to compute overall survival (OS). Both the ApoA-I and NLR were divided into three levels, according to their medians. A risk-stratified prediction model was established to evaluate the prognosis of patients with CRLM. The ROC curve AUC values were applied to evaluate the capability of the model. Results. Higher levels of ApoA-I and lower NLR were strongly associated with prolonged OS (Log-rank test, P < 0.05 ). The patients were then grouped into three queues according to the ApoA-I level and NLR. There was a crucial diversity in the OS ( P < 0.001 ) between the high-risk ( ApoA − I ≤ 1.03 g/L and NLR > 3.24 ), medium-risk ( ApoA − I > 1.03 g/L or NLR ≤ 3.24 ) and low-risk groups ( ApoA − I > 1.03 g/L and NLR ≤ 3.24 ). The AUC value of the prediction model ( AUC = 0.623 , 95% CI: 0.557-0.639, P = 0.001 ) was higher than other individual indicators (including ApoA-I, NLR, cT classification, and cN classification). Additionally, the association of the prediction model and cTN classification ( AUC = 0.715 , 95% CI: 0.606-0.708, P < 0.001 ) was better than the model and cTN classification alone. Conclusion. The combination of ApoA-I level and NLR could be a prognostic indicator for CRLM.
- 27 September 2022
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2022, 1-13
Open AccessThe Prognostic Value of Serum Apolipoprotein A-I Level and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Liver Metastasis
Background. Colorectal cancer liver metastasis (CRLM) is a high degree of malignancy with rapid disease progression and has a poor prognosis. Both serum apolipoprotein A-I (ApoA-I) and neutrophil-to-lymphocyte ratio (NLR) play key roles in anti-inflammation and antitumor. This study is aimed at evaluating the implication of serum ApoA-I level in combination with NLR in the prognosis of CRLM. Methods. We retrospectively analyzed the serum ApoA-I level and NLR in 237 patients with CRLM. Cox regression analyses were used to identify the independent prognostic significance of these indicators. Kaplan-Meier method and Log-rank test were applied to compute overall survival (OS). Both the ApoA-I and NLR were divided into three levels, according to their medians. A risk-stratified prediction model was established to evaluate the prognosis of patients with CRLM. The ROC curve AUC values were applied to evaluate the capability of the model. Results. Higher levels of ApoA-I and lower NLR were strongly associated with prolonged OS (Log-rank test, P < 0.05 ). The patients were then grouped into three queues according to the ApoA-I level and NLR. There was a crucial diversity in the OS ( P < 0.001 ) between the high-risk ( ApoA − I ≤ 1.03 g/L and NLR > 3.24 ), medium-risk ( ApoA − I > 1.03 g/L or NLR ≤ 3.24 ) and low-risk groups ( ApoA − I > 1.03 g/L and NLR ≤ 3.24 ). The AUC value of the prediction model ( AUC = 0.623 , 95% CI: 0.557-0.639, P = 0.001 ) was higher than other individual indicators (including ApoA-I, NLR, cT classification, and cN classification). Additionally, the association of the prediction model and cTN classification ( AUC = 0.715 , 95% CI: 0.606-0.708, P < 0.001 ) was better than the model and cTN classification alone. Conclusion. The combination of ApoA-I level and NLR could be a prognostic indicator for CRLM.
- 22 May 2022
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 108-109, S25
Structure-activity relationship of pyrazol-4-yl-pyridine derivatives for imaging the muscarinic acetylcholine receptor M4
- 22 May 2022
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 108-109, S25
Structure-activity relationship of pyrazol-4-yl-pyridine derivatives for imaging the muscarinic acetylcholine receptor M4
- Open Access
- 27 April 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAFV600E Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report
A vast majority of colorectal cancer (CRC) patients with microsatellite stability (MSS) or proficient mismatch repair (pMMR) are refractory to immunotherapeutic strategies. The current research focusses on the combined treatment strategies for identification and optimization in order to improve the efficacy of immunotherapy among patients with microsatellite stability (MSS), who account for the majority of metastatic colorectal cancer (mCRC) cases. mCRC patients harboring MSS and the BRAFV600E mutation show a worse prognosis and barely benefit from immunotherapy. In this report, we discuss the case of a mCRC patient with MSS and BRAFV600E mutation, who exhibited significant response to the combined treatment with nivolumab and bevacizumab, and has been exhibiting a progression-free survival (PFS) of more than 17 months. Our findings indicate that combined anti-angiogenic therapy can improve the efficacy of immunotherapy, which results in the prolong survival of the patient. This is a case report on MSS and BRAFV600E colorectal cancer which presents with a response to immunotherapy and anti-angiogenic therapy.
- 27 April 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessMetastatic Colorectal Cancer Patient With Microsatellite Stability and BRAFV600E Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report
A vast majority of colorectal cancer (CRC) patients with microsatellite stability (MSS) or proficient mismatch repair (pMMR) are refractory to immunotherapeutic strategies. The current research focusses on the combined treatment strategies for identification and optimization in order to improve the efficacy of immunotherapy among patients with microsatellite stability (MSS), who account for the majority of metastatic colorectal cancer (mCRC) cases. mCRC patients harboring MSS and the BRAFV600E mutation show a worse prognosis and barely benefit from immunotherapy. In this report, we discuss the case of a mCRC patient with MSS and BRAFV600E mutation, who exhibited significant response to the combined treatment with nivolumab and bevacizumab, and has been exhibiting a progression-free survival (PFS) of more than 17 months. Our findings indicate that combined anti-angiogenic therapy can improve the efficacy of immunotherapy, which results in the prolong survival of the patient. This is a case report on MSS and BRAFV600E colorectal cancer which presents with a response to immunotherapy and anti-angiogenic therapy.
- 3 January 2021
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 147 (3) , 767-777
Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling
Purpose Approximately 60% of patients with melanoma harbor BRAF mutation and targeting BRAF offers enormous advance in the treatment of those patients. Unfortunately, the efficacy of the BRAF inhibitors is usually restricted by the onset of drug resistance. Therefore, better understanding of the adaptive drug resistance mechanisms is essential for the development of alternative therapeutic strategies, and offers more promising measures to promote the short duration of response to BRAF inhibitors. Methods The levels of tumor suppressive long noncoding RNA on chromosome 8p12 (TSLNC8) were evaluated by qPCR. The MTT assay, colony formation assay, apoptosis assay, and in vivo xenograft tumor model were performed to assess the functions of TSLNC8 on drug resistance. Western blotting, RNA pull-down, and RNA immunoprecipitation (RIP) assays were applied to investigate the mechanisms of TSLNC8 in melanoma. Results Herein, our findings demonstrate that TSLNC8 is significantly downregulated in BRAF inhibitor-resistant melanoma tissues and cells. Moreover, downregulation of TSLNC8 in BRAF inhibitor sensitive cells reduces the toxicity response to BRAF inhibitor PLX4720, and inhibits apoptosis of melanoma cells-treated with PLX4720. Further assay elucidates that TSLNC8 can bind with the catalytic subunit of protein phosphatase 1α (PP1α) to regulate its distribution, and Downregulation of TSLNC8 results in PP1α cytoplasmic accumulation, thus re-activating the MAPK signaling. Eventually, the overexpression of TSLNC8 in BRAF inhibitor PLX4720-resistant melanoma cells restores the sensitive to BRAF inhibitor. Conclusion Collectively, our research provides a compelling rationale for resistance to BRAF inhibitor in melanoma, and the patient might benefit from the combinatorial therapy of BRAF inhibitors and lncRNA TSLNC8.
- 3 January 2021
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 147 (3) , 767-777
Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling
Purpose Approximately 60% of patients with melanoma harbor BRAF mutation and targeting BRAF offers enormous advance in the treatment of those patients. Unfortunately, the efficacy of the BRAF inhibitors is usually restricted by the onset of drug resistance. Therefore, better understanding of the adaptive drug resistance mechanisms is essential for the development of alternative therapeutic strategies, and offers more promising measures to promote the short duration of response to BRAF inhibitors. Methods The levels of tumor suppressive long noncoding RNA on chromosome 8p12 (TSLNC8) were evaluated by qPCR. The MTT assay, colony formation assay, apoptosis assay, and in vivo xenograft tumor model were performed to assess the functions of TSLNC8 on drug resistance. Western blotting, RNA pull-down, and RNA immunoprecipitation (RIP) assays were applied to investigate the mechanisms of TSLNC8 in melanoma. Results Herein, our findings demonstrate that TSLNC8 is significantly downregulated in BRAF inhibitor-resistant melanoma tissues and cells. Moreover, downregulation of TSLNC8 in BRAF inhibitor sensitive cells reduces the toxicity response to BRAF inhibitor PLX4720, and inhibits apoptosis of melanoma cells-treated with PLX4720. Further assay elucidates that TSLNC8 can bind with the catalytic subunit of protein phosphatase 1α (PP1α) to regulate its distribution, and Downregulation of TSLNC8 results in PP1α cytoplasmic accumulation, thus re-activating the MAPK signaling. Eventually, the overexpression of TSLNC8 in BRAF inhibitor PLX4720-resistant melanoma cells restores the sensitive to BRAF inhibitor. Conclusion Collectively, our research provides a compelling rationale for resistance to BRAF inhibitor in melanoma, and the patient might benefit from the combinatorial therapy of BRAF inhibitors and lncRNA TSLNC8.
- Open Access
- 16 January 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-9
Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial
Background: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC) patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the First Affiliated Hospital of Guangzhou University of Chinese Medicine as an internal preparation for CRF and is associated with a promising response. Due to the lack of high-quality clinical evidence, a randomized placebo-controlled trial is required to assess the efficacy and safety of JPSS. Methods/design: The efficacy and safety of JPSS herbal formula cream will be evaluated through a prospective, randomized, placebo-controlled trial conducted in the First Affiliated Hospital of Guangzhou University of Chinese Medicine. NSCLC patients with CRF will be randomized into two groups at a ratio of 1:1. Each group will receive either 15 g of the oral JPSS herbal formula cream or placebo twice a day from day 6 to day 20 during two courses of paclitaxel + platinum/docetaxel + platinum/pemetrexed + platinum (TP/DP/AP) chemotherapy. The primary endpoint is the difference in the degree of fatigue between baseline (the day before the start of the intervention) and day 42, which will be assessed by the Revised Piper Fatigue Scale score. The secondary endpoints are quality of life (measured by the 43-item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Lung Cancer C43), Eastern Cooperative Oncology Group Performance Status, and Traditional Chinese Medicine syndrome score. The toxicity of the treatments will also be evaluated at the same time. All outcomes will be measured at baseline, day 6, day 21, and day 42 of the treatment. Discussion: This randomized trial will investigate the efficacy and safety of JPSS applied for CRF in patients with NSCLC. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900023451. Registered on 28 May 2019.
- 16 January 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-9
Open AccessEfficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial
Background: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC) patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the First Affiliated Hospital of Guangzhou University of Chinese Medicine as an internal preparation for CRF and is associated with a promising response. Due to the lack of high-quality clinical evidence, a randomized placebo-controlled trial is required to assess the efficacy and safety of JPSS. Methods/design: The efficacy and safety of JPSS herbal formula cream will be evaluated through a prospective, randomized, placebo-controlled trial conducted in the First Affiliated Hospital of Guangzhou University of Chinese Medicine. NSCLC patients with CRF will be randomized into two groups at a ratio of 1:1. Each group will receive either 15 g of the oral JPSS herbal formula cream or placebo twice a day from day 6 to day 20 during two courses of paclitaxel + platinum/docetaxel + platinum/pemetrexed + platinum (TP/DP/AP) chemotherapy. The primary endpoint is the difference in the degree of fatigue between baseline (the day before the start of the intervention) and day 42, which will be assessed by the Revised Piper Fatigue Scale score. The secondary endpoints are quality of life (measured by the 43-item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Lung Cancer C43), Eastern Cooperative Oncology Group Performance Status, and Traditional Chinese Medicine syndrome score. The toxicity of the treatments will also be evaluated at the same time. All outcomes will be measured at baseline, day 6, day 21, and day 42 of the treatment. Discussion: This randomized trial will investigate the efficacy and safety of JPSS applied for CRF in patients with NSCLC. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900023451. Registered on 28 May 2019.
- 31 December 2017
- Published by Walter de Gruyter GmbH
- p. 35-58
1. Anti-Imperialism and Film Censorship During the Nanjing Decade, 1927–1937
- 31 December 2017
- Published by Walter de Gruyter GmbH
- p. 35-58
1. Anti-Imperialism and Film Censorship During the Nanjing Decade, 1927–1937
- Open Access
- 1 January 2017
- Published by Atlantis Press SARL
Increased Performance of Single-Chamber Air Cathode Microbial Fuel Cell Using Power Management System
- 1 January 2017
- Published by Atlantis Press SARL
Open AccessIncreased Performance of Single-Chamber Air Cathode Microbial Fuel Cell Using Power Management System